Novel Biomarkers in Inflammatory Bowel Disease

Study Overview
=================
Brief Summary
-----------------
The inflammatory bowel diseases represent a heterogeneous group of chronic , relapsing- inflammatory disorders of the gastrointestinal tract. Crohn's disease and ulcerative colitis are the two major clinical forms.The global incidence and prevalence of the inflammatory bowel diseases has increased over the last 2-4 decades . Despite the great progress in understanding the pathogenesis of these diseases, their etiology remains unclear . Considerable effort has been devoted to the development of an accurate ,noninvasive biomarkers that have increased diagnostic sensitivity and specificity . Osteoprotegerin is a member of the Tumor Necrosis Factor Receptor superfamily of proteins. Osteoprotegerin is of particular importance in bone metabolism, inflammation , tumorigenesis, and other processes where cell differentiation, survival, and death are controlled. Osteoprotegerin activates inflammation in the gut by stimulating immune cells, cytokines, and the Necrosis factor-κappaB pathway . Soluble Receptor activator of nuclear factor kappa-Β ligand is known as a type II membrane protein and as a member of tumor necrosis factor superfamily . Soluble Receptor activator of nuclear factor kappa-Β ligand has been identified to affect the immune system and a binding partner of ( Osteoprotegerin ), and controls cell proliferation.The interactions between Osteoprotegerin and Soluble Receptor activator of nuclear factor kappa-Β ligand, Soluble Receptor activator of nuclear factor kappa-Β have relevance to inflammatory pathways. Soluble Receptor activator of nuclear factor kappa-Β ligand- Soluble Receptor activator of nuclear factor kappa-Β ligand binding activates pathways that contribute to the survival of T-lymphocytes and dendritic cells .

Detailed Description
-----------------
The inflammatory bowel diseases represent a heterogeneous group of chronic , relapsing-remitting inflammatory disorders of the gastrointestinal tract, and Crohn's disease and ulcerative colitis are among the two major clinical forms The global incidence and prevalence of The inflammatory bowel diseases has increased over the last 2-4 decades, likely because of the adoption of a more western lifestyle as well as improved detection and awareness . Despite the great progress in understanding the pathogenesis of these diseases, their etiology remains unclear. Genetic, immune, and environmental factors are thought to play a key role . In the case of Crohn's disease , chronic inﬂammation can be localized in every gastrointestinal tract segment and involves the full thickness of the intestinal wall. In contrast ,in ulcerative colitis , mucosa and submucosa membranes of the large intestine are usually involved The illness starts in the rectum and generally extends proximally through the whole colon. . Both diseases differ in the localization and size of the segment involved. There are also differences in clinical image, laboratory test results, and different characteristics of complications. The course and grade of disease activity depend on many factors, such as environmental influences , genetic features, changes in the intestinal microbiota ecosystem, and immune factors . The correct diagnosis of non-specific inflammatory bowel diseases as well as the determination of disease activity, risk stratification , and prediction of response to therapy still relies on a multidisciplinary approach based on clinical, laboratory, endoscopic, and histologic examination . However, considerable effort has been devoted to the development of an accurate panel of noninvasive bio markers that have increased diagnostic sensitivity and specificity . Osteoprotegerin , also known as is a member of the Tumor Necrosis Factor Receptor superfamily of proteins. Osteoprotegerin is involved in many biological processes: its role is of particular importance in bone metabolism, inflammation , tumorigenesis, and other processes where cell differentiation, survival, and death are controlled. Osteoprotegerin was detected in serum, mucosal biopsies, and in the stool . The Osteoprotegerin gene is located on chromosome 8q23- 24.17. The mature OPG protein contains 380 amino acids and consists of seven domains. The ﬁrst four domains (D1-D4) contain cysteine-rich structures at the N terminus which are required for the inhibition of osteoclast differentiation. The ﬁfth and the sixth domain (D5 and D6) are death-domains and may be important in cytotoxic signals. The seventh domain, a C terminus heparin-binding site, is involved in dimer osteoprotegerin formation . Osteoprotegerin can be produced by a wide range of cell types, including osteoblasts, B lymphocytes, dendritic cells, bone marrow stromal cells, epithelial cells, and monocytes/macrophages. Osteoprotegerin activates and/or perpetuates inflammation in the gut by stimulating immune cells, cytokines, and the Necrosis factor-kappa B pathway . On the other hand, soluble Receptor activator of nuclear factor kappa-Β ligand , also known as tumor necrosis factor ligand. soluble Receptor activator of nuclear factor kappa-Β ligand is known as a type II membrane protein and as a member of tumor necrosis factor superfamily. Soluble Receptor activator of nuclear factor kappa-Β ligand has been identified to affect the immune system and control bone regeneration and remodeling, a binding partner of , and controls cell proliferation. it is expressed in several tissues and organs including: skeletal muscle, thymus, liver, colon, small intestine, adrenal gland, osteoblast, mammary gland epithelial cells, prostate and pancreas. Variation in concentration levels of soluble Receptor activator of nuclear factor kappa-Β ligand throughout several organs reconfirms the importance of in tissue soluble Receptor activator of nuclear factor kappa-Β ligand growth (particularly bone growth) and immune functions within the body . The interactions between ,Osteoprotegerin,soluble Receptor activator of nuclear factor kappa-Β ligand and soluble Receptor activator of nuclear factor kappa-Β also have relevance to inflammatory pathways. - soluble binding Receptor activator of nuclear factor kappa-Β binding activates several pathways that contribute to the survival of T-lymphocytes and dendritic cells . In addition, Osteoprotegerin is synthesized by dendritic and B-lymphocytes whereas soluble Receptor activator of nuclear factor kappa-Β ligand is mainly produced by T-lymphocytes. Moreover, soluble Receptor activator of nuclear factor kappa-Β ligand and various cytokines e.g. Tumor Necrosis Factor α induce the synthesis of osteoprotegerin from immune cells. In turn, the interruption of soluble Receptor activator of nuclear factor kappa-Β - soluble Receptor activator of nuclear factor kappa-Β ligand ligation by osteoprotegerin down regulates T-lymphocyte and dendritic activity, thereby modulating inﬂammatory responses . Calprotectin is a group of protein heterocomplexes.These proteins are expressed mainly in neutrophil and monocyte cytosols. Calprotectin stands for 60% of the circulating neutrophil cytosolic proteins, and is also present in monocytes and macrophages as well as in the tissue eosinophils of the ileum. Peripheral blood monocytes expose calprotectin both intra- and extracellularly, but neutrophils only intracellularly. Calprotectin shows antibacterial, antifungal, immunomodulatory, and antiproliferative action. Moreover, it potentially is a chemotactic factor for neutrophils. Calprotectin concentration in serum increases in disorders with an increase in neutrophil action. Neutrophils possess the ability to transmigrate the intestinal wall; that way calprotectin may be present in the stool. It has been shown that calprotectin concentration markedly increases in bowel disorders, such as (Crohn's disease ulcerative Colitis, and colonic neoplasia).

Official Title
-----------------
Novel Biomarkers in Diagnosis of Inflammatory Bowel Disease

Conditions
-----------------
Inflammatory Bowel Diseases

Intervention / Treatment
-----------------
* Diagnostic Test: Osteoprotegerin marker in serum in inflammatory bowel disease


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newly diagnosed patients (untreated) by clinical and endoscopic examination and not received treatment . Exclusion Criteria: patients have autoimmune diseases patients with cancer

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Osteoprotegerin marker in serum in inflammatory bowel disease|I will measure Osteoprotegerin and Soluble Receptor activator of nuclear factor kappa-Β ligand markers in serum of patient with inflammatory bowel disease|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| level of Osteoprotegerin and sRANKL in newly diagnosed patients with inflammatory bowel disease | measuring level of Osteoprotegerin and sRANKL in newly diagnosed patients with inflammatory bowel disease then it will measured again after treated with infliximab | 2 years |